Hemophilia and Von Willebrand Disease

Hemophilia and Von Willebrand Disease

Hemophilia and Von Willebrand Disease

On this page

Overview & Genetics - Bleeding Blueprint

  • Hemophilia: X-linked recessive disorders affecting clotting factors.
    • Hemophilia A: Factor VIII (FVIII) deficiency. More prevalent.
    • Hemophilia B (Christmas Disease): Factor IX (FIX) deficiency.
  • Von Willebrand Disease (vWD): Most common inherited bleeding disorder; typically Autosomal Dominant.
    • Quantitative or qualitative defect in von Willebrand Factor (vWF).
    • vWF roles: Essential for platelet adhesion to injury sites; carrier and stabilizer for FVIII.

⭐ vWD is the most common inherited bleeding disorder, impacting primary hemostasis (platelet function) and often FVIII levels (secondary hemostasis component).

Hemophilia Genetic Inheritance

Hemophilia (A & B) - Royal Pains

  • X-linked recessive:
    • Hemophilia A: Factor VIII (FVIII) deficiency. 📌 "Aight" for Eight.
    • Hemophilia B (Christmas Disease): Factor IX (FIX) deficiency. 📌 "Be-Nign" for B-Nine.
  • Clinical: Hemarthrosis (knees, elbows), muscle hematomas, prolonged bleeding post-trauma/surgery. ICH is critical.
  • Labs: ↑aPTT; normal PT, BT, platelets. Factor assays confirm.
  • Severity (Factor levels):
    • Severe: <1 IU/dL (<1%) - spontaneous bleeds.
    • Moderate: 1-5 IU/dL (1-5%) - bleeds post mild trauma.
    • Mild: >5-40 IU/dL (5-40%) - bleeds post surgery/major trauma.

⭐ Hemarthrosis is the hallmark of severe hemophilia, often starting when toddlers begin to walk.

Von Willebrand Disease - Sticky Platelets

  • Most common inherited bleeding disorder; primarily autosomal dominant.
  • Pathophysiology: Deficiency or dysfunction of von Willebrand Factor (vWF).
    • vWF functions: Mediates platelet adhesion to subendothelium (vWF ↔ GpIb), carrier for Factor VIII (protects FVIII from degradation).
  • Clinical: Predominantly mucocutaneous bleeding (epistaxis, gingival bleeding, menorrhagia, easy bruising). Hemarthrosis is rare (unlike hemophilia).
  • Types:
    • Type 1: Partial quantitative vWF deficiency (most common, ~75%).
    • Type 2: Qualitative vWF defect (2A, 2B, 2M, 2N).
    • Type 3: Near-complete or total vWF deficiency (severe, autosomal recessive).
  • Labs: ↑ Bleeding Time (BT), Normal or ↑ aPTT (due to ↓FVIII), Normal PT.

    ⭐ The Ristocetin cofactor assay (vWF:RCo) is the most specific test for vWF functional activity.

Diagnosis & Differentiation - Lab Clues

  • Core Panel: PT (normal), Platelet count (normal).
  • Hemophilia A/B: Hallmark is isolated ↑ aPTT. Bleeding Time (BT) is normal. Definitive: Specific ↓ Factor VIII (A) or ↓ Factor IX (B) assays.
  • Von Willebrand Disease (VWD): BT typically prolonged (↑). aPTT can be normal or ↑ (if FVIII significantly low). Key tests: ↓ vWF antigen (vWF:Ag), ↓ vWF activity (e.g., Ristocetin Cofactor - vWF:RCo), multimer analysis.

    ⭐ Mixing study: Patient plasma + Normal plasma corrects aPTT in factor deficiency (Hemophilia), not with inhibitors.

Management & Complications - Stop the Bleed!

  • Acute Bleed Management:
    • RICE (Rest, Ice, Compression, Elevation).
    • Antifibrinolytics (Tranexamic acid, EACA).
    • Hemophilia A: Factor VIII. Goal: 30-50% (minor), 80-100% (major). DDAVP (0.3 mcg/kg) for mild cases.
    • Hemophilia B: Factor IX. Goal: 30-50% (minor), 80-100% (major).
    • VWD: DDAVP (Type 1), vWF-FVIII concentrates (Type 2/3, or DDAVP ineffective).
  • Prophylaxis: Regular factor infusions for severe Hemophilia prevents spontaneous bleeds.
  • Key Complications:
    • Hemophilia: Inhibitor development, arthropathy (recurrent hemarthrosis).
    • VWD: Menorrhagia, post-op/dental bleeds.

    ⭐ DDAVP is contraindicated in VWD Type 2B (risk of thrombocytopenia) and Type 3 (ineffective).

High‑Yield Points - ⚡ Biggest Takeaways

  • Hemophilia A (↓Factor VIII) & B (↓Factor IX): X-linked recessive; cause hemarthrosis.
  • Von Willebrand Disease (vWD): most common inherited bleeding disorder (autosomal dominant); mucocutaneous bleeding.
  • Labs: PTT prolonged in both. Bleeding time prolonged in vWD (normal in hemophilia). PT normal.
  • Desmopressin (DDAVP) for mild Hemophilia A & Type 1 vWD.
  • Treatment: Hemophilia with factor concentrates. vWD with DDAVP, cryoprecipitate, or vWF concentrates.
  • Mixing study corrects PTT in factor deficiency.

Practice Questions: Hemophilia and Von Willebrand Disease

Test your understanding with these related questions

Which of the following statements regarding von Willebrand disease is incorrect?

1 of 5

Flashcards: Hemophilia and Von Willebrand Disease

1/10

Hb _____ levels are increased in juvenile chronic myeloid leukemia (JMML)

TAP TO REVEAL ANSWER

Hb _____ levels are increased in juvenile chronic myeloid leukemia (JMML)

F

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial